癌症相关通路和静脉血栓形成的生物标志物的关系  

The relationship of cancer-associated pathways and biomarkers of venous thrombosis

作　　者：蒋敏瑞 龚国清[1] JIANG Minrui;GONG Guoqing(Department of Pharmacology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学药理学研究室

出　　处：《药学研究》2019年第5期275-279,共5页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.81373415)

摘　　要：癌症患者具有更高的静脉血栓(VTE)风险。这篇综述总结了癌症患者中常见和癌症特异性的静脉血栓途径。白细胞、血小板和活性组织因子(TF^+)微泡(MV)水平的增加都是增加癌症相关血栓形成的潜在因素。不同类型癌症中白细胞增多症、血小板增多症、中性粒细胞、可溶性P-选择素、纤溶酶原激活物抑制剂1型(PAI-1)、活性组织因子微泡都与静脉血栓具有一定关联。对癌症患者静脉血栓形成途径的充分了解能够为抗血栓提供新的思路与方法,并且降低癌症血栓的发病率和死亡率。Cancer patients have an increased risk of venous thromboembolism(VTE).In this review,we summarize common and cancer type–specific pathways of VTE in cancer patients.Increased levels of leukocytes,platelets,and tissue factor–positive(TF^+) microvesicles(MVs) are all potential factors that alone or in combination increase cancer-associated thrombosis.In different types of cancer,leukocytosis,thrombocytosis,neutrophils,soluble P-selectin,PAI-1,TF^+ MV are all associated with VTE.A better understanding of the pathways that increase VTE in cancer patients may lead to the development of new therapies to reduce the morbidity and mortality associated with thrombosis.

关 键 词：癌症 静脉血栓 白细胞 血小板 组织因子 

分 类 号：R730.3[医药卫生—肿瘤]